PAZOPANIB

Background Information:

Pazopanib is a second-generation multi-targeted tyrosine kinase receptor inhibitor against VEGFR-1, -2 -3, PDGFR-α/β and c-kit.

Reference:

1. Jeldres C, Sun M, Perrotte P, Karakiewicz PI. Pazopanib trial data
cannot support first-line use. Nat Rev Urol. 2010 Jun;7(6):307-8.
2. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E,
Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann
RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase
II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive
Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer. J Clin
Oncol. 2010 Jun 1. [Epub ahead of print] PubMed PMID: 20516450.
3. Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC, Ivy SP.
Profound Hair and Skin Hypopigmentation in an African American Woman
Treated With the Multi-Targeted Tyrosine Kinase Inhibitor Pazopanib. J
Clin Oncol. 2010 Jun 1. [Epub ahead of print] PubMed PMID: 20516434.

APIM050219: PAZOPANIB

CAS No.: 444731-52-6.
Molecular Formula: C₂₁H₂₃N₇O₂S.
Molecular Weight: 437.52.
Purity: >99.5% (HPLC).
QC: HPLC, ¹HNMR, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.